This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Humana (HUM) Beats Q2 Earnings and Revenue Estimates
by Zacks Equity Research
Humana (HUM) delivered earnings and revenue surprises of 13.04% and 1.16%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
Strength Seen in Humana (HUM): Can Its 3.2% Jump Turn into More Strength?
by Zacks Equity Research
Humana (HUM) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
The Joint (JYNT) Acquires 4 Franchised Facilities, Down 5%
by Zacks Equity Research
The Joint (JYNT) anticipates the new acquisition value in Scottsdale to match the price of its previous purchases.
The Joint Corp. (JYNT) Reports Q1 Loss, Misses Revenue Estimates
by Zacks Equity Research
The Joint Corp. (JYNT) delivered earnings and revenue surprises of -125% and 1.93%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Humana (HUM) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
Humana (HUM) delivered earnings and revenue surprises of 17.72% and 1.78%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Centene (CNC) Q1 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Centene (CNC) delivered earnings and revenue surprises of 8.93% and 7.21%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
UnitedHealth Group (UNH) Q1 Earnings and Revenues Top Estimates
by Zacks Equity Research
UnitedHealth (UNH) delivered earnings and revenue surprises of 1.67% and 1.92%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
The Joint (JYNT) Buys Northern California Regional Developer Zone
by Zacks Equity Research
The Joint (JYNT) expects the Northern California region to hold 75 clinics, including its right to oversee 56 franchisee clinics.
Molina (MOH) to Join S&P 500 Driven by Medicare Performance
by Zacks Equity Research
Molina Healthcare (MOH) is likely to leave S&P MidCap 400 and replace IHS Markit Ltd. in the S&P 500 Index.
The Joint Corp. (JYNT) Q4 Earnings Lag Estimates
by Zacks Equity Research
The Joint Corp. (JYNT) delivered earnings and revenue surprises of -87.50% and 1.01%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
The Zacks Analyst Blog Highlights Teladoc Health, Albireo Pharma and The Joint Corp
by Zacks Equity Research
Teladoc Health, Albireo Pharma and The Joint Corp are included in this blog.
Fulgent Genetics (FLGT) to Post Q4 Earnings: What's in Store?
by Zacks Equity Research
In terms of COVID-19 NGS revenues, Fulgent Genetics (FLGT) is expected to have witnessed a rise in testing volume on increased demand through the Q4 months.
Medtronic (MDT) to Report Q3 Earnings: What's in Store?
by Zacks Equity Research
Medtronic (MDT) might report low procedure volumes in the fiscal third quarter in markets where its technologies are used in more deferrable procedures.
The Joint Corp. (JYNT) Expected to Beat Earnings Estimates: What to Know Ahead of Q4 Release
by Zacks Equity Research
The Joint Corp. (JYNT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
What's in Store for Teladoc's (TDOC) Q4 Earnings?
by Zacks Equity Research
Teladoc Health's (TDOC) Q4 results are expected to gain from high sales and visits volume.
Wall Street Analysts Think The Joint Corp. (JYNT) Could Surge 84%: Read This Before Placing a Bet
by Zacks Equity Research
The consensus price target hints at an 84.3% upside potential for The Joint Corp. (JYNT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Mednax (MD) Pursues $1.1B Transactions to Reduce Debt Burden
by Zacks Equity Research
Mednax (MD) issues senior notes, and a new revolving credit facility coupled with a term loan remains in place, which is aimed at reducing MD's debt level and associated interest expenses.
Molina Healthcare (MOH) Q4 Earnings Beat on Higher Premiums
by Zacks Equity Research
Molina Healthcare (MOH) expects its 2022 business to witness reduced impacts from COVID. Strong Medicare and Medicaid performance is set to buoy results.
Molina (MOH) Q4 Earnings and Revenues Top Estimates
by Zacks Equity Research
Molina (MOH) delivered earnings and revenue surprises of 2.13% and 3.97%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Merck (MRK) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Merck (MRK) delivered earnings and revenue surprises of 23.29% and 7.29%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Humana (HUM) Q4 Earnings Surpass Estimates
by Zacks Equity Research
Humana (HUM) delivered earnings and revenue surprises of 0.81% and 0.62%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Will The Joint Corp. (JYNT) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
The Joint Corp. (JYNT) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
The Joint Corp. (JYNT) Moves 9% Higher: Will This Strength Last?
by Zacks Equity Research
The Joint Corp. (JYNT) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
The Joint Corp. (JYNT) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
The Joint Corp. (JYNT) delivered earnings and revenue surprises of 225.00% and 7.76%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Analysts Estimate The Joint Corp. (JYNT) to Report a Decline in Earnings: What to Look Out for
by Zacks Equity Research
The Joint Corp. (JYNT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.